Stay Up-To-Date with Shivanka

Enhancing access to treatment for Gaucher disease in India: The need for indigenous manufacturing.

Preclinical characterization of SHRN1126, a novel, differentiated and steroidal oral selective estrogen receptor degrader (SERD).

Pharmacological Profiling of KSHN001034 – A novel prodrug of Fulvestrant with improved efficacy.

The evolving story of phenazopyridine: Exploring the pharmacological effects in animal models of interstitial cystitis/bladder pain syndrome.

Comparative analysis of approved and undertrial SERDs in estrogen receptor-α (ERα): An in-silico approach.

KSHN001034: An intramuscular prodrug of fulvestrant to treat estrogen-receptor (ER) positive advanced metastatic breast cancer.

Development of orally bioavailable prodrugs of fulvestrant for the treatment of metastatic/advanced breast cancer.